Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.49 |
| ▸ | PARP1 | P09874 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482111 | 0.84 | CHEK1 (0.63) | MEN1KMT2ACHEK1PARP1CYP3A4 | |
| SCHEMBL5470780 | 0.83 | CD274 (0.47) | MEN1KMT2ACHEK1 | |
| SCHEMBL5475386 | 0.82 | CHEK1 (0.56) | CHEK1 | |
| SCHEMBL5469695 | 0.81 | CHEK1 (0.58) | CHEK1 | |
| SCHEMBL5465367 | 0.81 | AKT1 (0.46) | CHEK1 | |
| SCHEMBL5469901 | 0.80 | L3MBTL1 (0.47) | CHEK1L3MBTL1HTT | |
| SCHEMBL5475886 | 0.78 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL5473293 | 0.77 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL5470085 | 0.77 | CHEK1 (0.51) | MEN1KMT2ACHEK1PARP1 | |
| SCHEMBL5480654 | 0.76 | CHEK1 (0.49) | MEN1KMT2ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | MEN1 941/4885KMT2A 3224/4885CHEK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.